Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
- Resource Type
- Article
- Source
- Lancet Respiratory Medicine; Dec2021, Vol. 9 Issue 12, p1407-1418, 12p
- Subject
BARICITINIB COVID-19 ADULTS MORTALITY DEATH rate - Language
- ISSN
- 22132600